In the last decade, several studies have explored the potential for novel biomarkers for early detection of pancreatic cancer. These markers extend from metabolites to genetic mutations, standalone or combination panels and use varied sample sources with a general aim to move towards non-invasive testing. However, these markers lack stringent validation and are not included in treatment guidelines. To answer the need for diagnostic and risk markers in pancreatic cancer, it is important to sift through all the emerging markers and identify the ones which hold promise over others. An exploration of these biomarkers in Excelra's database-biomarker insights, reveals all the emerging biomarkers and allows their selection and prioritization based on several factors, so that the ones with potential for clinical validation stand out.